Inicia sesión Registrate Mi Biblioteca idioma

Idioma

biblioteca idioma abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará la selección de artículos sobre Trastornos del Movimiento clasificados según los 11 tipos establecidos por International Parkinson & Movement Disorder Society.

Corea y enfermedad de Huntington

440 ARTíCULOS , VIENDO DEL 31 AL 45

PUBMED

Prefrontal executive function associated coupling relates to Huntington's disease stage.

Unschuld PG, Liu X, Shanahan M, Margolis RL, Bassett SS, Brandt J, Schretlen DJ, Redgrave GW, Hua J, Hock C, Reading SA, van Zijl PC, Pekar JJ, Ross CA.

Cortex. 2013 Nov-Dec;49(10):2661-73. doi: 10.1016/j.cortex.2013.05.015.

0

0

0

PUBMED

The influence of gender on phenotype and disease progression in patients with Huntington's disease.

Zielonka D, Marinus J, Roos RA, De Michele G, Di Donato S, Putter H, Marcinkowski J, Squitieri F, Bentivoglio AR, Landwehrmeyer GB.

Parkinsonism Relat Disord. 2013 Feb;19(2):192-7. doi: 10.1016/j.parkreldis.2012.09.012.

0

0

0

PUBMED

Prefrontal activity in Huntington's disease reflects cognitive and neuropsychiatric disturbances: the IMAGE-HD study.

Gray MA, Egan GF, Ando A, Churchyard A, Chua P, Stout JC, Georgiou-Karistianis N.

Exp Neurol. 2013 Jan;239:218-28. doi: 10.1016/j.expneurol.2012.10.020.

0

0

0

PUBMED

[Choreatic syndrome at 79 years old: late manifestation of Huntington's chorea].

Vachalova I, Golden V, Großkopf J, Heckmann JG.

Nervenarzt. 2013 Dec;84(12):1502-3. doi: 10.1007/s00115-013-3948-8. German. No abstract available.

0

0

0

PUBMED

Huntington's disease: easing the NMDAR traffic jam.

Daggett A, Yang XW.

Nat Med. 2013 Aug;19(8):971-3. doi: 10.1038/nm.3283. No abstract available.

0

0

0

PUBMED

Evaluation of exclusion prenatal and exclusion preimplantation genetic diagnosis for Huntington's disease in the Netherlands.

van Rij MC, de Die-Smulders CE, Bijlsma EK, de Wert GM, Geraedts JP, Roos RA, Tibben A.

Clin Genet. 2013 Feb;83(2):118-24. doi: 10.1111/cge.12058.

0

0

0

PUBMED

Predictive gene testing for Huntington disease and other neurodegenerative disorders.

Wedderburn S, Panegyres PK, Andrew S, Goldblatt J, Liebeck T, McGrath F, Wiltshire M, Pestell C, Lee J, Beilby J.

Intern Med J. 2013 Dec;43(12):1272-9. doi: 10.1111/imj.12176.

0

0

0

PUBMED

A small molecule TrkB ligand reduces motor impairment and neuropathology in R6/2 and BACHD mouse models of Huntington's disease.

Simmons DA, Belichenko NP, Yang T, Condon C, Monbureau M, Shamloo M, Jing D, Massa SM, Longo FM.

J Neurosci. 2013 Nov 27;33(48):18712-27. doi: 10.1523/JNEUROSCI.1310-13.2013. Erratum in: J Neurosci. 2014 Jan 29;34(5):2012.

0

0

0

PUBMED

Family history in juvenile Huntington disease: do the signs point to yes" or "very doubtful"?"

Lehman RK, Nance M.

Neurology. 2013 Mar 12;80(11):976-7. doi: 10.1212/WNL.0b013e31828728ce.

0

0

0

PUBMED

The Q175 mouse model of Huntington's disease shows gene dosage- and age-related decline in circadian rhythms of activity and sleep.

Loh DH, Kudo T, Truong D, Wu Y, Colwell CS.

PLoS One. 2013 Jul 30;8(7):e69993. doi: 10.1371/journal.pone.0069993.

0

0

0

PUBMED

In vitro and in vivo models of Huntington's disease show alterations in the endocannabinoid system.

Bari M, Battista N, Valenza M, Mastrangelo N, Malaponti M, Catanzaro G, Centonze D, Finazzi-Agrò A, Cattaneo E, Maccarrone M.

FEBS J. 2013 Jul;280(14):3376-88. doi: 10.1111/febs.12329.

0

0

0

PUBMED

MAP kinase phosphatase 1 (MKP-1/DUSP1) is neuroprotective in Huntington's disease via additive effects of JNK and p38 inhibition.

Taylor DM, Moser R, Régulier E, Breuillaud L, Dixon M, Beesen AA, Elliston L, Silva Santos Mde F, Kim J, Jones L, Goldstein DR, Ferrante RJ, Luthi-Carter R.

J Neurosci. 2013 Feb 6;33(6):2313-25. doi: 10.1523/JNEUROSCI.4965-11.2013.

0

0

0

PUBMED

β-Defensin Genomic Copy Number Does Not Influence the Age of Onset in Huntington's Disease.

Vittori A, Orth M, Roos RA, Outeiro TF, Giorgini F, Hollox EJ; REGISTRY investigators of the European Huntington’s Disease Network..

J Huntingtons Dis. 2013 Mar 27;2(1):107-124.

0

0

0

PUBMED

Experience with intramuscular zuclopenthixol and medroxyprogesterone acetate in the treatment of agitation and aggression in Huntington's disease.

Rej S, Desautels R.

J Neuropsychiatry Clin Neurosci. 2013 Summer;25(3):E33-4. doi: 10.1176/appi.neuropsych.12070164. No abstract available.

0

0

0

PUBMED

CNR1 variation is associated with the age at onset in Huntington disease.

Kloster E, Saft C, Epplen JT, Arning L.

Eur J Med Genet. 2013 Aug;56(8):416-9. doi: 10.1016/j.ejmg.2013.05.007.

0

0

0

Comentarios

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo HONcode Logo WIS

En colaboración con:

Zambon Neuroacademy